Insulin-Degrading Enzyme Inhibition, a Novel Therapy for Type 2 Diabetes?

Safia Costes; Peter C. Butler

doi:10.1016/j.cmet.2014.07.016

Retour

Insulin-Degrading Enzyme Inhibition, a Novel Therapy for Type 2 Diabetes?

Article de revue

Avec comité de lecture

Insulin-Degrading Enzyme Inhibition, a Novel Therapy for Type 2 Diabetes?

Safia Costes et Peter C. Butler

Cell metabolism, Vol.20(2), pp.201-203

05/08/2014

DOI: https://doi.org/10.1016/j.cmet.2014.07.016

PMID: 25100059

Résumé

Cell Biology

Endocrinology & Metabolism

Life Sciences & Biomedicine

Science & Technology

The insulin-degrading enzyme (IDE) has been identified as a type 2 diabetes and Alzheimer's disease susceptibility gene, though its physiological function remains unclear. Maianti et al. (2014) now propose that an IDE inhibitor may be a promising therapeutic strategy for type 2 diabetes.

Indicateurs

1 Consultations de la notice

Détails

Titre: Insulin-Degrading Enzyme Inhibition, a Novel Therapy for Type 2 Diabetes?
Créateurs - sans rôle: Safia Costes - Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA
Peter C. Butler - Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA
Détails de publication: Cell metabolism, Vol.20(2), pp.201-203
Éditeur: Elsevier
Nombre de pages: 4
Note de subvention: P30 DK041301; R01 DK059579 / NIDDK NIH HHS; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) R01DK059579 / NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)
Identifiants: 99163119209311
Unité académique: Institut de Génomique Fonctionnelle - IGF
Langue: English
Type de ressource: Journal article